Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...
Psychedelicnewsbreaks Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 ...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 m ...
Pharmaceutical Technology15 天
ITI-1284 by Intra-Cellular Therapies for Generalized Anxiety Disorder (GAD): Likelihood of ...
ITI-1284 is under clinical development by Intra-Cellular Therapies and currently in Phase II for Generalized Anxiety Disorder (GAD).